Beta Bionics (BBNX) Non-Current Deffered Revenue (2023 - 2026)

Beta Bionics has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $3.5 million in Q2 2026.

• Quarterly Non-Current Deffered Revenue rose 29.36% year-over-year to $3.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 million (up 29.36% YoY) and the FY2025 annual result came in at $3.3 million, up 77.26% from the prior year.
• Non-Current Deffered Revenue rose to $3.5 million in Q2 2026 per BBNX's latest filing, from $3.4 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $3.5 million in Q2 2026 and troughed at $255000.0 in Q4 2023.
• A 4-year average of $2.5 million and a median of $2.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2026: Non-Current Deffered Revenue soared 629.41% in 2024, then gained 29.36% in 2026.
• Over 4 years, Non-Current Deffered Revenue stood at $255000.0 in 2023, then jumped by 629.41% to $1.9 million in 2024, then jumped by 77.26% to $3.3 million in 2025, then rose by 4.76% to $3.5 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $3.5 million, $3.4 million, and $3.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.